CTCX

Carmell Corporation (CTCX) | Rumor.io

Carmell

CTCX

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about CTCX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Jan 16

CTCX is being compared to GORO, with some investors selling CTCX for GORO.
CTCX is benefiting from the closing of its Skincare division.
CTCX is expected to see a 2-3X price range increase.

Generated by AI

Sentiment

Of the messages about CTCX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	100% +11.46
Bearish	—	—	—	0% -11.46

Bullish· Jan 3

$CTCX is expected to reach $1.75 by the end of the day tomorrow.
The stock has the potential for significant gains, with a 26.63% increase in share value since the new CEO took over and a catalyst for a weight loss drug additive that eliminates muscle wasting side effects.
A reversal on the 30-minute chart is expected, with some analysts predicting a move to $1.50-$2.00 next week.

Bearish· Jan 2

$CTCX may be unable to sustain a rally, as the downtrend may be a sign of a larger decline.
The stock's short sellers may be poised to lose, as the price may return to $0.28 or lower by next Monday or Tuesday.
The stock's frequent halts may be causing significant losses for retail investors, who are being shorted by hedge funds.

Generated by AI

Topics

Of the messages about CTCX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	45%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	55%

Announcements· Jan 2

Carmell Corporation (CTCX) has acquired Elevai Skincare's assets, including a $2.5M revenue portfolio and advanced stem cell tech, with CTCX shares surging +55% after the announcement.
The acquisition integrates one of the newest advances in stem cell-derived exosome technology into the Carmell platform, further solidifying its status as a leader in bio-aesthetic skincare science.
The purchase consideration includes approximately $1.1 million in Carmell common stock at the closing of the acquisition, with potential earnouts tied to future sales.

Technical Analysis· Jan 2

$CTCX is trading with a possible 3 drives pattern, and may be forming a bull flag or inverse head and shoulders pattern, which could indicate a bullish reversal.
The stock is showing signs of a healthier uptrend, with a curl up and potential for a bounce, and may be ready for a bullish reversal on a cup and handle pattern.
Key price levels to watch for $CTCX include $1.10, $1.20, and $1.28, with a stop loss at $1.05, and the stock may be due for a break above $1.00.

Generated by AI

Community

Of the messages about CTCX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	38.46%
Newcomers	—	—	—	61.54%

Regulars· Jan 2

The regulars are preparing for potential "hot press releases" from Carmell Therapeutics Corporation, specifically mentioning the 7am EST time frame as a common release time.
The acquisition of Elevai Skincare's assets by Carmell Therapeutics Corporation has contributed to a +55% increase in the company's stock price.
The acquired assets include a $2.5M revenue portfolio and advanced stem cell technology, which are seen as valuable additions to Carmell Therapeutics Corporation's portfolio.

Newcomers· Jan 2

New investors are being advised to wait before investing in Carmell Stock due to an upcoming analysis.
The analysis will determine the intrinsic value of the stock, which may influence investment decisions.
The stock's current market position is being considered by new investors as a factor in their potential investment.

Generated by AI

Also Discussed

Investors talking about CTCX also mention

#	Name	Attention
1	BioNexus Gene Lab Corp.BGLC	0%0
2	NewGenIvf Group Limited Class A Ordinary SharesNIVF	0%0
3	Bright Minds Biosciences Inc.DRUG	0%new
4	CytoMed Therapeutics Ltd.GDTC	0%0
5	ENTO - Entero Therapeutics, Inc.	——
6	FIAC - Focus Impact Acquisition Corp.	——
7	KACL - Kairous Acquisition Corp. Limited	——
8	TransCode Therapeutics, Inc.RNAZ	0%+0
9	CTLT - Catalent, Inc.	——
10	Expion360 Inc.XPON	0%0

Carmell Corporation

Location

United States

Social

What share of all stock conversation is about CTCX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Jan 16

CTCX is being compared to GORO, with some investors selling CTCX for GORO.
CTCX is benefiting from the closing of its Skincare division.
CTCX is expected to see a 2-3X price range increase.

Generated by AI

Sentiment

Of the messages about CTCX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	100% +11.46
Bearish	—	—	—	0% -11.46

Bullish· Jan 3

$CTCX is expected to reach $1.75 by the end of the day tomorrow.
The stock has the potential for significant gains, with a 26.63% increase in share value since the new CEO took over and a catalyst for a weight loss drug additive that eliminates muscle wasting side effects.
A reversal on the 30-minute chart is expected, with some analysts predicting a move to $1.50-$2.00 next week.

Bearish· Jan 2

$CTCX may be unable to sustain a rally, as the downtrend may be a sign of a larger decline.
The stock's short sellers may be poised to lose, as the price may return to $0.28 or lower by next Monday or Tuesday.
The stock's frequent halts may be causing significant losses for retail investors, who are being shorted by hedge funds.

Generated by AI

Topics

Of the messages about CTCX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	45%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	55%

Announcements· Jan 2

Carmell Corporation (CTCX) has acquired Elevai Skincare's assets, including a $2.5M revenue portfolio and advanced stem cell tech, with CTCX shares surging +55% after the announcement.
The acquisition integrates one of the newest advances in stem cell-derived exosome technology into the Carmell platform, further solidifying its status as a leader in bio-aesthetic skincare science.
The purchase consideration includes approximately $1.1 million in Carmell common stock at the closing of the acquisition, with potential earnouts tied to future sales.

Technical Analysis· Jan 2

$CTCX is trading with a possible 3 drives pattern, and may be forming a bull flag or inverse head and shoulders pattern, which could indicate a bullish reversal.
The stock is showing signs of a healthier uptrend, with a curl up and potential for a bounce, and may be ready for a bullish reversal on a cup and handle pattern.
Key price levels to watch for $CTCX include $1.10, $1.20, and $1.28, with a stop loss at $1.05, and the stock may be due for a break above $1.00.

Generated by AI

Community

Of the messages about CTCX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	38.46%
Newcomers	—	—	—	61.54%

Regulars· Jan 2

The regulars are preparing for potential "hot press releases" from Carmell Therapeutics Corporation, specifically mentioning the 7am EST time frame as a common release time.
The acquisition of Elevai Skincare's assets by Carmell Therapeutics Corporation has contributed to a +55% increase in the company's stock price.
The acquired assets include a $2.5M revenue portfolio and advanced stem cell technology, which are seen as valuable additions to Carmell Therapeutics Corporation's portfolio.

Newcomers· Jan 2

New investors are being advised to wait before investing in Carmell Stock due to an upcoming analysis.
The analysis will determine the intrinsic value of the stock, which may influence investment decisions.
The stock's current market position is being considered by new investors as a factor in their potential investment.

Generated by AI

Carmell

Social

Jan 16

Sentiment

Bullish· Jan 3

Bearish· Jan 2

Topics

Announcements· Jan 2

Technical Analysis· Jan 2

Community

Regulars· Jan 2

Newcomers· Jan 2

Also Discussed

Carmell Corporation

Company Information

Location

Also Discussed

Social

Jan 16

Sentiment

Bullish· Jan 3

Bearish· Jan 2

Topics

Announcements· Jan 2

Technical Analysis· Jan 2

Community

Regulars· Jan 2

Newcomers· Jan 2